William B Stallcup Selected Research

chondroitin sulfate proteoglycan 4

1/2018	Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
7/2017	Localization of VEGF to Vascular ECM Is an Important Aspect of Tumor Angiogenesis.
3/2017	NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations.
2/2016	NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.
1/2016	NG2 Proteoglycan Ablation Reduces Foam Cell Formation and Atherogenesis via Decreased Low-Density Lipoprotein Retention by Synthetic Smooth Muscle Cells.
1/2016	Role of NG2 proteoglycan in macrophage recruitment to brain tumors and sites of CNS demyelination.
4/2015	NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization.
1/2014	NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.
4/2012	Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.
1/2012	Ablation of NG2 proteoglycan leads to deficits in brown fat function and to adult onset obesity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William B Stallcup Research Topics

Disease

17	Neoplasms (Cancer) 01/2018 - 11/2002
7	Melanoma (Melanoma, Malignant) 05/2018 - 11/2005
6	Brain Neoplasms (Brain Tumor) 03/2017 - 12/2010
6	Demyelinating Diseases (Demyelinating Disease) 01/2017 - 12/2003
3	Glioma (Gliomas) 03/2017 - 05/2006
3	Spinal Cord Injuries (Spinal Cord Injury) 12/2014 - 04/2002
2	Cicatrix (Scar) 01/2022 - 04/2005
2	Fibrosis (Cirrhosis) 01/2022 - 01/2017
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 06/2013
2	Atherosclerosis 01/2016 - 05/2009
2	Obesity 01/2016 - 01/2012
2	Breast Neoplasms (Breast Cancer) 01/2015 - 06/2005
2	Corneal Neovascularization 04/2013 - 01/2004
2	Carcinogenesis 04/2012 - 06/2005
2	Atherosclerotic Plaque (Atheroma) 09/2010 - 05/2009
2	Inflammation (Inflammations) 07/2010 - 05/2009
1	Carcinoma (Carcinomatosis) 05/2018
1	Hyperlipidemias (Hyperlipidemia) 01/2016
1	Diabetic Retinopathy (Retinopathy, Diabetic) 02/2014
1	Open-Angle Glaucoma (Glaucoma, Open Angle) 02/2014
1	Neoplasm Metastasis (Metastasis) 06/2013
1	Vascular Tissue Neoplasms 03/2012
1	Oligodendroglioma 12/2010
1	Astrocytoma (Pilocytic Astrocytoma) 12/2010
1	Bites and Stings (Sting) 08/2010
1	Multiple Sclerosis 10/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2007
1	Leukemia 05/2007
1	Prostatic Neoplasms (Prostate Cancer) 05/2007
1	Hypoxia (Hypoxemia) 06/2005
1	Pathologic Neovascularization 01/2004

Drug/Important Bio-Agent (IBA)

14	chondroitin sulfate proteoglycan 4IBA 01/2018 - 01/2004
6	Proteoglycans (Proteoglycan)IBA 05/2018 - 04/2005
5	CollagenIBA 01/2022 - 11/2005
5	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2017 - 12/2003
5	Chondroitin Sulfate ProteoglycansIBA 12/2014 - 04/2002
4	Proteins (Proteins, Gene)FDA Link 05/2018 - 08/2010
3	Complement System Proteins (Complement)IBA 01/2022 - 08/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2017 - 06/2005
3	IntegrinsIBA 03/2017 - 01/2014
2	AntigensIBA 01/2016 - 08/2010
2	Apolipoproteins E (ApoE)IBA 01/2016 - 05/2009
2	Retinaldehyde (Retinal)IBA 02/2014 - 01/2004
2	LigandsIBA 06/2013 - 11/2005
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2012 - 06/2005
1	Anaphylatoxin C5a ReceptorIBA 01/2022
1	Green Fluorescent ProteinsIBA 01/2022
1	Complement Receptors (Complement Receptor)IBA 01/2022
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2022
1	Muramidase (Lysozyme)IBA 01/2022
1	Conditioned Culture MediaIBA 05/2018
1	perlecanIBA 05/2018
1	GlycosaminoglycansIBA 05/2018
1	ChondroitinIBA 05/2018
1	Insulin-Like Growth Factor Binding ProteinsIBA 01/2018
1	Actins (F Actin)IBA 01/2017
1	Clodronic Acid (Clodronate)IBA 01/2017
1	Peptides (Polypeptides)IBA 01/2016
1	cysteinylglycine (Cys-Gly)IBA 01/2016
1	arginyllysineIBA 01/2016
1	CadmiumIBA 01/2016
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2015
1	Collagen Type VIIBA 06/2013
1	LipidsIBA 01/2012
1	OligonucleotidesIBA 09/2010
1	HMW-MAAIBA 08/2010
1	Surface Antigens (Surface Antigen)IBA 08/2010
1	EpitopesIBA 08/2010
1	Monoclonal AntibodiesIBA 08/2010
1	AntibodiesIBA 08/2010
1	Epithelial Cell Adhesion MoleculeIBA 08/2010
1	Bispecific AntibodiesIBA 08/2010
1	CytokinesIBA 07/2010
1	Glatiramer Acetate (Copaxone)FDA Link 10/2009
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 05/2009
1	Aryldialkylphosphatase (Paraoxonase)IBA 05/2009
1	oxidized low density lipoproteinIBA 05/2009
1	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2009
1	Platelet-Derived Growth Factor alpha ReceptorIBA 07/2008
1	Non-Receptor Type 11 Protein Tyrosine PhosphataseIBA 05/2007
1	Protein Tyrosine PhosphatasesIBA 05/2007
1	phosphonic acidIBA 05/2007
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 05/2007
1	thiazolidine-2,4-dioneIBA 05/2007
1	4- (3- (1- adamantyl)- 4- hydroxyphenyl)- 3- chlorocinnamic acidIBA 05/2007
1	Hydroxamic Acids (Hydroxamic Acid)IBA 05/2007
1	Boronic AcidsIBA 05/2007
1	RetinoidsIBA 05/2007
1	1H-tetrazole (tetrazole)IBA 05/2007
1	Galectin 3 (LGALS3)IBA 05/2006
1	TOR Serine-Threonine KinasesIBA 06/2005
1	ErbB-2 ReceptorIBA 06/2005
1	Sirolimus (Rapamycin)FDA Link 06/2005
1	Calcitonin Gene-Related PeptideIBA 04/2005

Therapy/Procedure

3	Therapeutics 12/2010 - 08/2010
1	Immunotherapy 01/2018
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2017
1	Quantum Dots (Quantum Dot) 01/2016